Berenson J R, Lipton A
West Los Angeles Veterans Affairs Medical Center, Division of Hematology-Oncology, CA 90073, USA.
Curr Opin Oncol. 1998 Nov;10(6):566-71. doi: 10.1097/00001622-199811000-00015.
Tumor-induced osteolysis or lytic bone disease is mediated by osteoclast activation. Osteoclasts can be activated directly by products produced by tumors or indirectly through other nonmalignant cells. By reducing osteoclastic activity, bisphosphonates inhibit bone resorption. Because these agents were shown to be effective in treating other diseases associated with increased bone resorption, including cancer-related hypercalcemia and Paget's disease of bone, studies were initiated to explore the use of bisphosphonates in patients with osteolytic bone metastases.
肿瘤诱导的骨溶解或溶骨性骨病是由破骨细胞激活介导的。破骨细胞可被肿瘤产生的产物直接激活，或通过其他非恶性细胞间接激活。双膦酸盐通过降低破骨细胞活性来抑制骨吸收。由于这些药物已被证明对治疗其他与骨吸收增加相关的疾病有效，包括癌症相关的高钙血症和佩吉特骨病，因此开展了研究以探索双膦酸盐在溶骨性骨转移患者中的应用。
